Generated by AI
Roivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines and technologies through a portfolio of specialized subsidiary companies. Roivant Sciences Ltd. operates across immunology, dermatology, and other high-unmet-need therapeutic areas, with current work spanning commercial products and clinical-stage candidates. Its business model emphasizes creating focused operating companies to advance individual drug programs, support partnering activities, and incubate complementary health technology initiatives. The company’s current product and pipeline portfolio includes therapies for autoimmune and inflammatory diseases, as well as treatments being studied in areas such as dermatologic conditions, uveitis, pulmonary hypertension, and rare diseases. Roivant Sciences Ltd. plays a distinctive role in the healthcare market by combining drug development expertise with an asset-centric structure designed to move promising medicines toward commercialization.
Website11-12 St. James's Square
London, SW1Y 4LB
United Kingdom
The latest articles about ROIV.
Roivant Sciences reported second quarter 2026 revenue of US$35.12 million and a net loss of US$191.62 million, and confirmed completion of a US$393.94 million share repurchase program that retired 13,632,008 shares. The first commercial weeks of LISRIA generated US$31 million in net revenue and were accompanied by encouraging data readouts across IMVT-1402, Mosliciguat and brepocitinib, highlighting how Roivant Sciences is pairing clinical progress with early product uptake. We will now...
Summary of Oct 21's posts. Generated by AI.
Summary of Oct 21's posts. Generated by AI.
Summary of Oct 21's posts. Generated by AI.
Investors talking about ROIV also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.